UBS analyst Trung Huynh maintains $AbbVie (ABBV.US)$ with a hold rating, and adjusts the target price from $195 to $181.
According to TipRanks data, the analyst has a success rate of 72.7% and a total average return of 14.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $AbbVie (ABBV.US)$'s main analysts recently are as follows:
The recent adjustment in expectations for AbbVie, following the unexpected Phase 2 update on emraclidine, has led to its removal from revenue models and an increase in Cobenfy forecasts for another company. Despite this, the future growth trajectory for revenue and earnings per share remains unaltered for both entities.
The pivotal Phase 2 data for AbbVie's emraclidine did not meet expectations, as it failed to show a statistically significant change from baseline in the Positive and Negative Symptom Scale total score in studies for schizophrenia. This outcome was unexpected, particularly considering the drug was seen as a key asset from AbbVie's recent acquisition and was projected to generate substantial sales towards the decade's end, with potential competitive advantages against existing treatments.
Analysts note that following the outcome of the EMPOWER 1 and 2 Emraclidine Phase 2 studies in Schizophrenia, which resulted in placebo outperforming both active arms in the trials, the primary value proposition of the significant acquisition is effectively negated.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
瑞士银行分析师Trung Huynh维持$艾伯维公司 (ABBV.US)$持有评级，并将目标价从195美元下调至181美元。
根据TipRanks数据显示，该分析师近一年总胜率为72.7%，总平均回报率为14.5%。
此外，综合报道，$艾伯维公司 (ABBV.US)$近期主要分析师观点如下：
艾伯维公司最近对emraclidine意外的2期更新的预期进行调整，导致其从营业收入模型中被移除，并增加了对另一家公司Cobenfy预测的预期。尽管如此，对于营收和每股收益的未来增长轨迹对于这两家公司来说都保持不变。
艾伯维公司emraclidine关键的2期数据未达到预期，因为在用于精神分裂症研究的阳性和阴性症状量表总分的基线变化方面未显示出统计学上显著的变化。这一结果是意外的，特别是考虑到这种药物被视为艾伯维公司最近收购的关键资产，并被预计将在本十年结束前为公司带来可观的销售额，同时具有潜在的竞争优势对抗现有的治疗方法。
分析师指出，在精神分裂症的EMPOWER 1和2 emraclidine Phase 2研究结果公布后，安慰剂在试验中表现优于两个活性对照组，这显著收购的主要价值主张被有效地否定。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
